Key Themes and Breakthroughs at EAU26

1. The Future of Prostate Cancer Care: A 2050 Roadmap

Prostate cancer remains one of the most diagnosed malignancies in men worldwide, and EAU26 dedicated significant attention to redefining its management over the next quarter-century. Experts presented a consensus framework for personalized treatment strategies, emphasizing early detection, minimally invasive therapies, and long-term survivorship care. Key discussions included:

• Biomarker-Driven Diagnostics: Advances in liquid biopsy techniques were highlighted as a game-changer for detecting aggressive prostate cancer earlier and with greater precision. Researchers noted that these tools could reduce unnecessary biopsies by up to 30% while improving risk stratification.
• Focal Therapy Innovations: Techniques like high-intensity focused ultrasound (HIFU) and cryotherapy gained traction as alternatives to radical prostatectomy, particularly for localized disease. Data presented suggested these approaches could preserve urinary and sexual function in select patients without compromising oncological outcomes.
• AI and Machine Learning: Artificial intelligence (AI) models trained on large datasets were shown to predict treatment responses and recurrence risks with accuracy rivaling human experts. Clinicians stressed the need for regulatory frameworks to integrate AI into routine practice safely.

Dr. Monique Roobol, a leading epidemiologist in prostate cancer screening, underscored the importance of balancing innovation with accessibility: “The goal isn’t just to develop cutting-edge tools—it’s to ensure they reach patients in low-resource settings as well.”

2. Neurogenic Bladder: Challenges Across the Lifespan

Neurogenic bladder—a condition caused by nerve damage from spinal cord injuries, multiple sclerosis, or congenital disorders—was a focal point of EAU26’s functional urology track. Sessions explored the complexities of managing this condition from childhood to old age, with a focus on:

• Pediatric Considerations: Experts discussed the long-term risks of bladder augmentation surgery in children, including metabolic complications and the need for lifelong monitoring. Non-surgical alternatives, such as botulinum toxin injections and sacral neuromodulation, were presented as promising options for younger patients.
• Adult and Geriatric Care: For older adults, the interplay between neurogenic bladder and comorbidities like diabetes or dementia poses unique challenges. A review of recent studies highlighted the role of multidisciplinary teams—including urologists, neurologists, and physical therapists—in optimizing quality of life.
• Quality of Life Metrics: Patient-reported outcomes took center stage, with researchers advocating for standardized tools to measure the impact of treatments on daily living. “We’re moving beyond just clinical endpoints,” said Dr. John Heesakkers, a functional urology specialist. “The patient’s voice must guide our decisions.”

3. Rare and Complex Cases: Lessons from the Front Lines

EAU26 featured several case studies that pushed the boundaries of urological practice. Among the most discussed was the natural history of a giant bladder stone, a rare and often misdiagnosed condition. Key insights included:

• Diagnostic Delays: Presenters noted that giant bladder stones—defined as those larger than 4 cm—are frequently mistaken for tumors or other pathologies, leading to delayed treatment. Imaging techniques like CT urography were recommended for accurate diagnosis.
• Surgical Challenges: Open cystolithotomy remains the gold standard for removing large stones, but minimally invasive approaches, such as percutaneous cystolitholapaxy, are gaining traction for select cases. The importance of postoperative follow-up to prevent recurrence was emphasized.
• Underlying Causes: Chronic urinary retention, recurrent infections, and metabolic disorders were identified as common contributors. Addressing these root causes is critical to preventing recurrence.